Eiger BioPharmaceuticals Inc. (EIGR)

14.31
NASDAQ : Health Technology
Prev Close 13.31
Day Low/High 13.19 / 14.33
52 Wk Low/High 8.20 / 18.00
Avg Volume 121.70K
Exchange NASDAQ
Shares Outstanding 19.26M
Market Cap 260.40M
EPS -3.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Eiger Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At The International Liver Congress™ 2019

Eiger Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At The International Liver Congress™ 2019

- 36% Durable Virologic Response at 24 Weeks Post-Treatment

Eiger BioPharmaceuticals Management Team To Present And Participate In Jefferies HBV Investor Summit

Eiger BioPharmaceuticals Management Team To Present And Participate In Jefferies HBV Investor Summit

PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Clinigen And Eiger BioPharmaceuticals Launch Worldwide Managed Access Program For Lonafarnib For Patients With Progeria And Progeroid Laminopathies

Clinigen And Eiger BioPharmaceuticals Launch Worldwide Managed Access Program For Lonafarnib For Patients With Progeria And Progeroid Laminopathies

Clinigen Group plc (AIM:CLIN, 'Clinigen'), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc.

EIGR Crosses Above Key Moving Average Level

EIGR Crosses Above Key Moving Average Level

In trading on Monday, shares of Eiger BioPharmaceuticals Inc crossed above their 200 day moving average of $11.28, changing hands as high as $12.07 per share. Eiger BioPharmaceuticals Inc shares are currently trading up about 8.7% on the day.

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib In Progeria And Progeroid Laminopathies

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib In Progeria And Progeroid Laminopathies

- Survival Benefit in Children with Progeria Published in JAMA 2018

Eiger BioPharmaceuticals Reports On 2018 R&D Day

Eiger BioPharmaceuticals Reports On 2018 R&D Day

-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing

Eiger BioPharmaceuticals To Host R&D Day In New York City

Eiger BioPharmaceuticals To Host R&D Day In New York City

PALO ALTO, Calif., Dec.

Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA

Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA

In trading on Monday, shares of Eiger BioPharmaceuticals Inc crossed above their 200 day moving average of $11.12, changing hands as high as $11.22 per share. Eiger BioPharmaceuticals Inc shares are currently trading up about 4.5% on the day.

Eiger To Participate In Piper Jaffray Healthcare Conference

Eiger To Participate In Piper Jaffray Healthcare Conference

PALO ALTO, Calif., Nov.

Eiger BioPharmaceuticals Is Now Oversold (EIGR)

Eiger BioPharmaceuticals Is Now Oversold (EIGR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eiger Bio Reports Third Quarter 2018 Financial Results

Eiger Bio Reports Third Quarter 2018 Financial Results

- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019

Eiger BioPharmaceuticals To Participate At BTIG Biotech Conference

Eiger BioPharmaceuticals To Participate At BTIG Biotech Conference

PALO ALTO, Calif., Oct.

Eiger BioPharmaceuticals Announces Positive Results In Phase 2 PREVENT Study Of Avexitide Targeting GLP-1 In Post-Bariatric Hypoglycemia (PBH)

Eiger BioPharmaceuticals Announces Positive Results In Phase 2 PREVENT Study Of Avexitide Targeting GLP-1 In Post-Bariatric Hypoglycemia (PBH)

- Primary and Secondary Endpoints Achieved with Statistical Significance

Eiger BioPharmaceuticals To Participate In Investor Conferences

Eiger BioPharmaceuticals To Participate In Investor Conferences

PALO ALTO, Calif., Sept.

Eiger Announces FDA Guidance On HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

Eiger Announces FDA Guidance On HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection